OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity
Jean-Marc Schwarz, Susan M. Noworolski, Ayca Erkin‐Cakmak, et al.
Gastroenterology (2017) Vol. 153, Iss. 3, pp. 743-752
Open Access | Times Cited: 228
Jean-Marc Schwarz, Susan M. Noworolski, Ayca Erkin‐Cakmak, et al.
Gastroenterology (2017) Vol. 153, Iss. 3, pp. 743-752
Open Access | Times Cited: 228
Showing 1-25 of 228 citing articles:
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3319
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3319
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Thomas Jensen, Manal F. Abdelmalek, Shelby Sullivan, et al.
Journal of Hepatology (2018) Vol. 68, Iss. 5, pp. 1063-1075
Open Access | Times Cited: 781
Thomas Jensen, Manal F. Abdelmalek, Shelby Sullivan, et al.
Journal of Hepatology (2018) Vol. 68, Iss. 5, pp. 1063-1075
Open Access | Times Cited: 781
Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
Kasper W. ter Horst, Mireille J. Serlie
Nutrients (2017) Vol. 9, Iss. 9, pp. 981-981
Open Access | Times Cited: 328
Kasper W. ter Horst, Mireille J. Serlie
Nutrients (2017) Vol. 9, Iss. 9, pp. 981-981
Open Access | Times Cited: 328
Dietary carbohydrates: role of quality and quantity in chronic disease
David S. Ludwig, Frank B. Hu, Luc Tappy, et al.
BMJ (2018), pp. k2340-k2340
Open Access | Times Cited: 277
David S. Ludwig, Frank B. Hu, Luc Tappy, et al.
BMJ (2018), pp. k2340-k2340
Open Access | Times Cited: 277
Dietary Fructose and the Metabolic Syndrome
Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén
Nutrients (2019) Vol. 11, Iss. 9, pp. 1987-1987
Open Access | Times Cited: 243
Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén
Nutrients (2019) Vol. 11, Iss. 9, pp. 1987-1987
Open Access | Times Cited: 243
Non-alcoholic fatty liver disease: A patient guideline
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 207
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 207
Lifestyle modification in NAFLD/NASH: Facts and figures
Kate Hallsworth, Leon A. Adams
JHEP Reports (2019) Vol. 1, Iss. 6, pp. 468-479
Open Access | Times Cited: 205
Kate Hallsworth, Leon A. Adams
JHEP Reports (2019) Vol. 1, Iss. 6, pp. 468-479
Open Access | Times Cited: 205
Molecular aspects of fructose metabolism and metabolic disease
Mark A. Herman, Morris J. Birnbaum
Cell Metabolism (2021) Vol. 33, Iss. 12, pp. 2329-2354
Open Access | Times Cited: 193
Mark A. Herman, Morris J. Birnbaum
Cell Metabolism (2021) Vol. 33, Iss. 12, pp. 2329-2354
Open Access | Times Cited: 193
Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction
Dylan D. Thomas, Barbara E. Corkey, Nawfal W. Istfan, et al.
Journal of the Endocrine Society (2019) Vol. 3, Iss. 9, pp. 1727-1747
Open Access | Times Cited: 185
Dylan D. Thomas, Barbara E. Corkey, Nawfal W. Istfan, et al.
Journal of the Endocrine Society (2019) Vol. 3, Iss. 9, pp. 1727-1747
Open Access | Times Cited: 185
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 170
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 170
Metabolic drivers of non-alcoholic fatty liver disease
Kendra K. Bence, Morris J. Birnbaum
Molecular Metabolism (2020) Vol. 50, pp. 101143-101143
Open Access | Times Cited: 155
Kendra K. Bence, Morris J. Birnbaum
Molecular Metabolism (2020) Vol. 50, pp. 101143-101143
Open Access | Times Cited: 155
Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development
Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella
Nutrients (2021) Vol. 13, Iss. 5, pp. 1442-1442
Open Access | Times Cited: 139
Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella
Nutrients (2021) Vol. 13, Iss. 5, pp. 1442-1442
Open Access | Times Cited: 139
Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 11, pp. 708-722
Closed Access | Times Cited: 131
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 11, pp. 708-722
Closed Access | Times Cited: 131
Obesity II: Establishing causal links between chemical exposures and obesity
Jerrold J. Heindel, Sarah Howard, Keren Agay‐Shay, et al.
Biochemical Pharmacology (2022) Vol. 199, pp. 115015-115015
Open Access | Times Cited: 130
Jerrold J. Heindel, Sarah Howard, Keren Agay‐Shay, et al.
Biochemical Pharmacology (2022) Vol. 199, pp. 115015-115015
Open Access | Times Cited: 130
Obesity I: Overview and molecular and biochemical mechanisms
Robert H. Lustig, David Collier, Christopher D. Kassotis, et al.
Biochemical Pharmacology (2022) Vol. 199, pp. 115012-115012
Open Access | Times Cited: 125
Robert H. Lustig, David Collier, Christopher D. Kassotis, et al.
Biochemical Pharmacology (2022) Vol. 199, pp. 115012-115012
Open Access | Times Cited: 125
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 96
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 96
Obesogens: a unifying theory for the global rise in obesity
Jerrold J. Heindel, Robert H. Lustig, Sarah Howard, et al.
International Journal of Obesity (2024) Vol. 48, Iss. 4, pp. 449-460
Open Access | Times Cited: 33
Jerrold J. Heindel, Robert H. Lustig, Sarah Howard, et al.
International Journal of Obesity (2024) Vol. 48, Iss. 4, pp. 449-460
Open Access | Times Cited: 33
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 19
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 19
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 18
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 18
Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
Suzanne R. Sharpton, Bernd Schnabl, Rob Knight, et al.
Cell Metabolism (2020) Vol. 33, Iss. 1, pp. 21-32
Open Access | Times Cited: 130
Suzanne R. Sharpton, Bernd Schnabl, Rob Knight, et al.
Cell Metabolism (2020) Vol. 33, Iss. 1, pp. 21-32
Open Access | Times Cited: 130
Nonalcoholic Fatty Liver Disease in Children
Jake P. Mann, Luca Valenti, Eleonora Scorletti, et al.
Seminars in Liver Disease (2018) Vol. 38, Iss. 01, pp. 001-013
Open Access | Times Cited: 129
Jake P. Mann, Luca Valenti, Eleonora Scorletti, et al.
Seminars in Liver Disease (2018) Vol. 38, Iss. 01, pp. 001-013
Open Access | Times Cited: 129
Are Lifestyle Therapies Effective for NAFLD Treatment?
Nermeen N. El-Agroudy, Anica Kurzbach, Roman N. Rodionov, et al.
Trends in Endocrinology and Metabolism (2019) Vol. 30, Iss. 10, pp. 701-709
Open Access | Times Cited: 126
Nermeen N. El-Agroudy, Anica Kurzbach, Roman N. Rodionov, et al.
Trends in Endocrinology and Metabolism (2019) Vol. 30, Iss. 10, pp. 701-709
Open Access | Times Cited: 126
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Jan Borén, Chris J. Packard, Marja‐Riitta Taskinen
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 123
Jan Borén, Chris J. Packard, Marja‐Riitta Taskinen
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 123
Fructose-containing caloric sweeteners as a cause of obesity and metabolic disorders
Luc Tappy
Journal of Experimental Biology (2018) Vol. 221, Iss. Suppl_1
Open Access | Times Cited: 117
Luc Tappy
Journal of Experimental Biology (2018) Vol. 221, Iss. Suppl_1
Open Access | Times Cited: 117
Fructose contributes to the Warburg effect for cancer growth
Takahiko Nakagawa, Miguel A. Lanaspa, Íñigo San Millán, et al.
Cancer & Metabolism (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 110
Takahiko Nakagawa, Miguel A. Lanaspa, Íñigo San Millán, et al.
Cancer & Metabolism (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 110
